Table 3.

Genome-wide meta-analysis of overall test and/or interaction test with the stratified analysis for the association with hyperglycemia and multiple Cox regression for the genotypes of G6PC2 rs13431652, rs573225, and rs560887 for predicting breast cancer risk

SNPGenetic modelAllelea (Ref/Alt)ORbPbQbHRc (95% CI)P
G6PC2 rs13431652AllelicT/C0.796.99E−0.90.7061.13 (1.00–1.28)0.047
G6PC2 rs573225AllelicG/A1.251.34E−080.6071.17 (1.03–1.32)0.013
GA1.11 (0.94–1.32)0.22
AA1.41 (1.09–1.84)0.009
RecessiveGG + GA/AA1.34 (1.05–1.71)0.019
G6PC2 rs560887AllelicT/C1.253.17E−080.6121.19 (1.05–1.34)0.007
TC1.12 (0.95–1.34)0.181
CC1.47 (1.13–1.92)0.005
RecessiveTT + TC/CC1.39 (1.08–1.80)0.011
  • NOTE: Only SNPs that are significantly genome-wide associated with hyperglycemia in overall/interaction (G*E or subgroup) analysis and breast cancer were included. Numbers in bold face are statistically significant.

  • Abbreviations: Alt, alternative allele; Q, Cochran's Q; Ref, reference allele.

  • aAdditive genetic model regressed in genome-wide meta-analysis.

  • bResults from genome-wide meta-analysis of overall test for the association with hyperglycemia.

  • cHR adjusted by age, education, annual family income, family history of breast cancer, depressive symptom, smoking, physical activity, dietary alcohol in g/day, % calories from SFAs/day, BMI, waist-to-hip ratio, hysterectomy ever, ages at menarche and menopause, oral contraceptive use, exogenous estrogen–only use, and exogenous estrogen plus progestin use.